Investors share how early healthcare and life science startups can make the most of new opportunities
The webinar discussions plan the current capital markets, and how healthcare and life science investors and startups can best browse it. The webinar dialogue reveals the role of automation, alternative funding mechanisms and how these factors create new investment and funding opportunities. They also share how they view the differences between investment in health technologies, biopharmaceuticals and pharmaceutical technology.
MBX Capital Management Partner, Breyer Capital Partner Morgan Cheatham and Ben Kromnick Gurdane Bhutani, Head of Healthcare and Life Sciences at Fintech Business Mercury, shared their observations and outlooks as part of the webinar sponsored by Mercury. Artificial intelligence is not only an important part of drug development, from automating administrative tasks to determining the impact of drug development that can be reused by FDA-approved drugs, but also because of its impact on the time it takes to complete these tasks.
Butani notes that since developing drugs far exceeds the cost of product development in any other industry, any product that can reduce the R&D process has great value, which is why AI has developed such a strong interest in the biopharmaceutical sector.
“When you think about the value of AI, people talk a lot about speed, they talk a lot about cost. I go back to what Gurdane said: The most important metric we want to base AI on AI is increasing the likelihood of success of the program because it is with how we think about the net worth equation of the asset,” Bhutani,” Bhutani.
Kromnick observed that he saw a wave of innovation in private equity-owned hospitals and health systems. This is when academic medical centers are particularly challenged by government grant cuts.
Cheatham observed that although the capital market is currently “very close”, there is still a lot of capital on the institutional side as well as a lot of trading activity by institutional venture capital firms. He also noted that Breyer Capital often works with home offices and other organizations to support new companies.
To access the complete webinar record, complete the following form:
Mercury is a financial technology company, not a bank. Choose banking services provided by financial groups,,,,, List. ,, and Evolution Bank and Trust, Member FDIC.
picture: feodora chiosea, Getty Images
